Bruker Co. (NASDAQ:BRKR) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 11.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 247,355 shares of the medical research company’s stock after buying an additional 24,916 shares during the period. New York State Common Retirement Fund’s holdings in Bruker were worth $14,500,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BRKR. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Bruker by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 177 shares during the period. CIBC Asset Management Inc increased its holdings in Bruker by 5.6% in the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock valued at $248,000 after buying an additional 223 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 248 shares during the period. Blue Trust Inc. boosted its stake in shares of Bruker by 13.5% during the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company’s stock worth $127,000 after acquiring an additional 257 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Bruker by 2.1% in the 3rd quarter. US Bancorp DE now owns 12,700 shares of the medical research company’s stock worth $877,000 after acquiring an additional 260 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

Shares of BRKR opened at $50.82 on Monday. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86. The company’s 50 day simple moving average is $56.73 and its 200 day simple moving average is $60.03. The company has a market capitalization of $7.70 billion, a price-to-earnings ratio of 66.87, a PEG ratio of 2.16 and a beta of 1.16. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, sell-side analysts predict that Bruker Co. will post 2.69 EPS for the current year.

Analyst Upgrades and Downgrades

BRKR has been the subject of several research reports. Bank of America lifted their price objective on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. UBS Group assumed coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price objective on the stock. Barclays cut their target price on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, Citigroup lowered their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.